Worldwide Clinical Trials appoints vp, Oncology Medical Affairs

Gerald Messerschmidt joins firm from Talon Therapeutics

Worldwide Clinical Trials, a US provider of clinical research services based in King of Prussia, PA, has appointed Gerald Messerschmidt as vice president, Oncology Medical Affairs.

Messerschmidt has more than 20 years’ clinical and operational leadership in the development of critical therapies for a multitude of oncology indications, the firm said. His portfolio of experience includes small molecules, biologic products, medical devices, genetic modification of living organisms and immune modulation therapy.

Prior to joining Worldwide Clinical Trials, Messerschmidt held the position of vp, Clinical Development at Talon Therapeutics (formerly Hana Biosciences) where he co-led the successful development of Marqibo, a new liposome plus vincristine product. From 2008–2010, Messerschmidt held senior positions within oncology at Onyx Pharmaceuticals and Icon Clinical Research, preceded by leading Wild-Type Enterprises as chairman and ceo from 2000–2008.

You may also like

Regulatory

Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV

Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
Manufacturing

MedPharm completes FDA inspection of manufacturing plant in Durham

The topical drug product manufacturing facility in North Carolina successfully completed its FDA inspection for the commercial manufacture of drug products with no Form 483 issued plus an NAI classification
Manufacturing

New thermal inkjet printer expands AM Labels’ coding portfolio

M2 system delivers high resolution variable data printing at production-line speeds
Regulatory

Ascletis secures FDA IND clearance for Phase II Study of oral GLP-1 candidate in type 2 diabetes

Ascletis has received US FDA IND clearance to begin a 13-week Phase II trial of ASC30, its oral small-molecule GLP-1 receptor agonist, evaluating efficacy, safety and tolerability in people with type 2 diabetes
Regulatory

Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court

The company has welcomed a decision by China’s Supreme People’s Court affirming the validity of its semaglutide compound patent, strengthening confidence for foreign drugmakers operating in the Chinese market
Regulatory

Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt)

The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
Regulatory

Hansa Biopharma submits BLA to FDA for Imlifidase in desensitisation for kidney transplantation

Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response
Subscribe now